Keryx Biopharm Inc (KERX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2011 | 12-2010 | 09-2010 | 06-2010 | 03-2010 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -6,405 | -20,331 | -15,017 | -9,169 | -4,015 |
| Depreciation Amortization | 11 | 60 | 48 | 33 | 18 |
| Other Working Capital | 399 | 1,606 | 2,874 | 671 | -283 |
| Other Operating Activity | 573 | 2,457 | 2,071 | 1,458 | 681 |
| Operating Cash Flow | $-5,422 | $-16,208 | $-10,024 | $-7,007 | $-3,599 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -100 | 17,448 | 8,426 | 7,484 | 3,353 |
| PPE Investments | -25 | -23 | -18 | -6 | -4 |
| Sale Of Investment | N/A | 1,620 | 1,620 | 1,620 | N/A |
| Investing Cash Flow | $-125 | $19,045 | $10,028 | $9,098 | $3,349 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | N/A | 9,189 | 8,849 | 3,161 | N/A |
| Financing Cash Flow | $N/A | $9,189 | $8,849 | $3,161 | $N/A |
| Beginning Cash Position | 28,412 | 16,386 | 16,386 | 16,386 | 16,386 |
| End Cash Position | 22,865 | 28,412 | 25,239 | 21,638 | 16,136 |
| Net Cash Flow | $-5,547 | $12,026 | $8,853 | $5,252 | $-250 |
| Free Cash Flow | |||||
| Operating Cash Flow | -5,422 | -16,208 | -10,024 | -7,007 | -3,599 |
| Capital Expenditure | -25 | -23 | -18 | -6 | -4 |
| Free Cash Flow | -5,447 | -16,231 | -10,042 | -7,013 | -3,603 |